Pilot screening programme for small molecule activators of p53

Rachel G. Berkson, Jonathan J. Hollick, Nicholas J. Westwood, Julie A. Woods, David P. Lane, Sonia Lain

    Research output: Contribution to journalArticlepeer-review

    43 Citations (Scopus)


    Activation of the p53 tumour suppressor is predicted to have therapeutically beneficial effects. Many current anti-cancer therapies activate the p53 response via DNA damage. Non-genotoxic activation of the p53 pathway would open the way to long-term and possibly prophylactic treatments. We have established a simple protocol to screen small compound libraries for activators of p53-dependent transcription, and to select and characterise the most interesting hits, which include non-genotoxic activators. These compounds or their derivatives are of potential clinical interest. This approach may also lead to the identification of novel p53-activating compound families and possibly to the description of novel molecular pathways regulating p53 activity.
    Original languageEnglish
    Pages (from-to)701-710
    Number of pages10
    JournalInternational Journal of Cancer
    Issue number5
    Publication statusPublished - 2005


    • Transcription
    • Screening
    • Cancer-therapeutics


    Dive into the research topics of 'Pilot screening programme for small molecule activators of p53'. Together they form a unique fingerprint.

    Cite this